Immunome granted FDA review for tumor candidate
Seeking Alpha ·
Immunome ( IMNM ) announced on Wednesday that the U.S. FDA has accepted its marketing application for its lead asset, varegacestat, targeted at a group of noncancerous soft tissue lesions known as desmoid tumors. The new drug application, targeting adults with desmoid tumors
DYAX Investor Sentiment
Bullish (Long) 57% · Bearish (Short) 43%
331 participants
Related News
- Earnings season will prove 'durability of growth' for chip stocks
- New York AG sues 3M, DuPont, others over PFAS ‘forever chemicals’
- The Bancorp jumps 7% after KBW rating upgrade
- Forget AI bubble: SocGen warns of a Japan bond crisis
- Why Meta Stock Dropped -- Then Bounced Back
- Market Trends and Investment Opportunities in the U.S. Data Center Market, 2026-2031, Featuring 213 IT & Support Infrastructure Providers and Contractors